Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648201 | 1.00 | HPGD (0.55) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL28735599 | 0.98 | HPGD (0.53) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL29765632 | 0.82 | HPGD (0.59) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL432918 | 0.79 | MEN1 (0.54) | NOTUMKMT2ACYP1A2MEN1CYP2A6 | |
| SCHEMBL30722457 | 0.76 | HPGD (0.49) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL30642159 | 0.76 | HPGD (0.57) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL3641405 | 0.76 | HPGD (0.57) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL1464486 | 0.76 | HPGD (0.57) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL3195836 | 0.74 | RNASEH1 (0.60) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL1462133 | 0.74 | HPGD (0.55) | HPGDNOTUMDDB1CRBNKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115960085-A | Preparation method of fluoro-oxindole heterocyclic compound | 杭州职业技术学院 | 2023-04-14 | — | — | CN | claimed |
| EP-2723336-B1 | COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME | CENTRE NAT RECH SCIENT (FR) | 2020-04-08 | — | — | EP | claimed |
| CN-108383853-B | A kind of donor material based on fluorine-containing Oxoindole and preparation method thereof and device | 南京工业大学 | 2019-11-22 | — | — | CN | claimed |
| US-10435366-B2 | Compositions for the treatment of Fragile X syndrome | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-10-08 | — | — | US | claimed |
| CN-110194833-A | For causing the catalyst system of lactide ring-opening polymerisation and the preparation method of polylactic acid | 中国科学技术大学 | 2019-09-03 | — | — | CN | claimed |
| US-10265300-B2 | Methods of treating seizure disorders | OVID THERAPEUTICS INC. (US) | 2019-04-23 | — | — | US | claimed |
| US-20180243266-A1 | METHODS OF TREATING SEIZURE DISORDERS | OVID THERAPEUTICS INC. | 2018-08-30 | — | — | US | claimed |
| WO-2018157046-A1 | METHODS OF TREATING SEIZURE DISORDERS | OVID THERAPEUTICS INC. (US) | 2018-08-30 | — | — | WO | claimed |
| CN-104093715-B | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | 埃科特莱茵药品有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-20140221450-A1 | Compositions for the treatment of Fragile X syndrome | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-08-07 | — | — | US | claimed |
| EP-1330426-A4 | SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050043293-A1 | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof | GRIBKOFF VALENTIN K (US) | 2005-02-24 | — | — | US | claimed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| EP-1441722-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-04 | — | — | EP | claimed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | claimed |
| EP-1330426-A1 | SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2002072088-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-19 | — | — | WO | claimed |
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2002030868-A1 | SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| US-20020045566-A1 | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | KCNQ5, KCNQ2, KCNQ1 | HPGD 2724/4885NOTUM 2753/4885DDB1 3861/4885 |
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | HPGD 2482/4885NOTUM 2523/4885DDB1 454/4885 |
| US-10265300-B2 | Methods of treating seizure disorders | KCNJ2, HCN2, CACNA1I | HPGD 1505/4885NOTUM 1731/4885DDB1 4567/4885 |
| US-20180243266-A1 | METHODS OF TREATING SEIZURE DISORDERS | KCNJ2, HCN2, CACNA1I | HPGD 1505/4885NOTUM 1731/4885DDB1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.